Two subsequent phase 2 studies, TUSCANY and ARTEMIS-UC, explored different monoclonal antibodies directed against TL1A in adult patients with IBD refractory or intolerant to standard and/or advanced therapies. This evidence concerns the gene TNFSF15 and inflammatory bowel disease.